- Research article
- Open Access
Tumorigenic potential of pituitary tumor transforming gene (PTTG) in vivoinvestigated using a transgenic mouse model, and effects of cross breeding with p53 (+/−) transgenic mice
BMC Cancer volume 12, Article number: 532 (2012)
Pituitary tumor-transforming gene (PTTG) is an oncogene that is overexpressed in variety of tumors and exhibits characteristics of a transforming gene. Previous transgenic mouse models to access the tumorigenic potential in the pituitary and ovary have resulted in dysplasia without formation of visible tumors, possibly due to the insufficient expression of PTTG. PTTG expression level is critical for ovarian tumorigenesis in a xenograft model. Therefore, the tumorigenic function of PTTG in vivo remains unclear. We generated a transgenic mouse that overexpresses PTTG driven by the CMV promoter to determine whether PTTG functions as a transforming oncogene that is capable of initiating tumorigenesis.
Transgenic animals were generated by microinjection of PTTG transgene into the male pronucleus of FVB 0.5 day old embryos. Expression levels of PTTG in tissues of transgenic animals were analyzed using an immunohistochemical analysis. H&E staining and immunohistostaining were performed to examine the type of tumor in transgenic and PTTG transgenic/p53+/- animals.
PTTG transgenic offspring (TgPTTG) were monitored for tumor development at various ages. H&E analysis was performed to identify the presence of cancer and hyperplastic conditions verified with the proliferation marker PCNA and the microvessel marker CD31. Immunohistochemistry was performed to determine transgene expression, revealing localization to the epithelium of the fallopian tube, with more generalized expression in the liver, lung, kidney, and spleen. At eight months of age, 2 out of 15 TgPTTG developed ovarian cancer, 2 out of 15 developed benign tumors, 2 out of 15 developed cervical dysplasia, and 3 out of 15 developed adenomyosis of the uterus. At ten months of age, 2 out of 10 TgPTTG developed adenocarcinoma of the ovary, 1 out of 10 developed a papillary serous adenocarcinoma, and 2 out of 10 presented with atypia of ovarian epithelial cells. Tumorigenesis is a multi-step process, often requiring multiple oncogenes and/or inactivation of tumor suppressor genes. Therefore, to understand the contribution of p53 to PTTG induced tumorigenesis, we crossbred TgPTTG to p53+/− mice and maintained those 8 to 10 months. TgPTTG/p53+/− animals developed sarcomas faster than p53+/− alone as well as different tumor types in addition to cervical carcinomas in situ in 10 out of 17 females.
We conclude that while PTTG is a functional transforming oncogene, it requires an additional partner to effectively promote tumorigenesis through the loss of p53 include or between function or modulation.
The pituitary tumor transforming gene (PTTG), also known as securin, is ubiquitously expressed at a low basal level where it functions in regulating sister chromatid separation . Its physiologic functions include cell proliferation, ensuring the fidelity of DNA replication, DNA damage repair, organ development, and metabolism . Overexpression of PTTG influences multiple pathways for cancer initiation and progression including enhanced cell proliferation , genomic instability , and cellular transformation [3, 5]. Its transforming ability has been demonstrated in vitro where over-expression of PTTG induces anchorage-independent growth in soft agar and in vivo xenograft tumor formation in nude mice using rat fibroblast NIH3T3 cells and human embryonic kidney HEK293 cells [3, 5]. PTTG overexpression has been correlated with the promotion of angiogenesis through increased expression and secretion of several factors including basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and interleukin 8 (IL-8) [3, 6, 7]. PTTG is implicated in metastasis through the induction of the epithelial to mesenchymal transition [8, 9].
PTTG overexpression has been identified in a variety of endocrine-related tumors, including pituitary, ovarian, uterine, breast, and thyroid [5, 6, 10, 11] and non-endocrine related tumors such as lung, gastrointestinal, and gliomas. PTTG expression is also detected in germ cell tumors, sex-cord and stromal cell tumors, epithelial tumors arising from the ovary and in multiple types of breast cancer, including invasive ductal carcinomas, ductal in situ carcinomas, and infiltrating ductal carcinomas . In pituitary adenomas, PTTG is implicated in tumor initiation and progression . It has also been identified as an oncogene in pituitary tumors activated in the early stages of cellular transformation, from normal to hyperplastic , and has been correlated with tumor invasiveness . Levels of PTTG expression have also been correlated to the degree of malignancy, pathogenesis, and progression of colorectal, thyroid, and breast tumors [14–16]. In the case of gliomas, PTTG has been correlated to poor prognosis in patients . PTTG is abundantly expressed in several carcinoma cell lines including cervical carcinoma HeLa cells, choriocarcinomas JEG-3 and JAR, breast adenocarcinoma MCF-7, osteogenic sarcoma U-2OS, hepatocellular carcinoma Hep 3B, lung carcinoma H1299, EY and A549, ovarian CAOV3 and A2780, and thyroid carcinoma TC-1 [18, 19]. These finding indicate that PTTG may be involved in transformation of several tissues leading to tumorigenesis.
Transgenic PTTG−/− mice exhibit pituitary hypoplasia and, upon cross-breeding with heterozygous deletion of retinoblastoma (Rb+/−), show a tumor development rate of 30%. Comparatively Rb+/−/PTTG+/+ develop tumors at 86% by 13 months of age . PTTG silencing using siRNA on xenograft tumors from an ovarian cancer cell line and hepatocellular carcinoma cell line reduced both the size and incidence of tumor burden; however, incomplete silencing of PTTG led to a reduction of tumor burden, while complete silencing showed nearly complete eradication of tumors, indicating that PTTG expression impacts tumor formation and tumor growth [19, 21].
Previously, our lab developed a transgenic mouse model that over-expresses human PTTG cDNA under the control of Müllerian inhibiting substance type II receptor (MISIIR). These mice presented with an increased mass of the corpus luteum as well as an increase in serum LH and testosterone, but failed to generate visible ovarian tumors , possibly due to a weak promoter that was unable to produce the required level of PTTG protein to initiate tumorigenesis. In addition, Abbud et al.  generated a PTTG transgenic mouse under the control of the alpha-subunit of glycoprotein hormone (αGSU) to target expression to the gonadotroph cells of the pituitary, resulting in gonadroph hyperplasia and microadenomas with plurihormal hyperplasia, accompanied by prostatic and seminal vesicle hyperplasia. Tumorigenesis often requires multiple gene mutations including activation or amplification of oncogenes, increased growth factors and their receptors, and/or inactivation of tumor suppressor genes. As such, PTTG expression by itself may not be sufficient to drive tumorigenesis and may require a partner gene . Therefore, in our current study, we have selected the CMV promoter to drive expression of human PTTG cDNA to produce PTTG transgenic (TgPTTG) mice to understand the tumorigenic potential of PTTG in vivo. In addition, we crossbred TgPTTG with p53+/− mice. TgPTTG mice developed ovarian adenocarcinomas and adenocarcinoma of the fallopian tube. Crossbreeding of TgPTTG with p53+/− mice resulted in enhanced tumor incidence, earlier tumor formation, and carcinomas in situ of the cervix.
Construction of CMV-PTTG-EGFP transgene
Human PTTG cDNA was subcloned into the multiple cloning site of the pEGFP-N3 vector containing the CMV promoter and EGFP reporter gene. The vector was restricted using Ase I and Afl II restriction enzymes (New England BioLabs) by incubating with the vector for 2 h at 37°C. The restricted vector was run on a 0.7% agarose gel to isolate the transgene fragment, CMV-PTTG-EGFP (Figure 1). CMV-PTTG-EGFP was excised from the gel and purified using a gel extraction kit (Qiagen). CMV-PTTG-EGFP was then sequenced to test the authenticity of the sequence.
Mice were housed in a conventional facility with a 12 h light: 12 h darkness cycle and fed standard chow and water ad libdum. All animals were treated in accordance with National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and approved by Institutional Animal Care and Use Committee (IACUC) at the University of Louisville.
Generation of transgenic animals
Transgenic animals were generated in association with the University of Cincinnati Transgenic Mouse Core Facility. Transgene DNA was microinjected into the male pronucleus of FVB 0.5 day old embryos. Embryos were then transplanted into a pseudo-pregnant female. Wild type males were bred to positive TgPTTG female founders. TgPTTG F1 males were bred to wild type females to establish a colony line.
P53+/− mice on an FVB background were obtained from Jackson Laboratory. Female p53+/− were crossbred with male TgPTTG mice from the same founder line (#71309) to generate TgPTTG/p53+/− mice.
Genotyping and screening of transgenic and p53+/−mice
Mice were tail clipped between 21–28 days of age and toe tattooed with an ID number. DNA from tail clips was extracted using PCR Extract-N-Amp kit (Sigma). PTTG-EGFP genotype was identified via PCR using the specific primer: PTTG 16182: sense 5’-ACT GAG AAG ACT GTT AAA GC-3’ or PTTG 16207: sense 5’-ACG AAT TCA TGG CTA CTC TGA TCT ATG T-3’, and EGFP antisense 23759: 5’- AGA TGA ACT TCA GGG TCA GC-3’ that specifically amplified the transgene sequence (Figure 1). Two PTTG sense primers were used to verify accuracy of amplification. PCR conditions were 1) 94°C for 5 min, 2) 94°C for 30 sec, 3) 58°C for 30 sec, 4) 72°C for 1 min, 5) steps 2–4 were repeated for 30 cycles, 6) 72°C for 7 min. P53+/− genotype was identified via PCR using the specific primers according to Jackson Laboratory protocol: Wild type: sense 5’-ACA GCG TGG TAC CTT AT-3’, Common: antisense 5’- TAT ACT CAG AGC CGG CCT -3’, and Mutant: sense 5’-CTA TCA GGA CAT AGC GTT GG-3’. PCR conditions were 1) 94°C for 3 min, 2) 94°C for 30 sec, 3) 64°C for 1 min, 4) 72°C for 1.5 min, 5) Steps 2–4 repeated for 35 cycles, 6) 72°C for 2 min.
RNA isolation and analysis of transgene expression via RT-PCR
Tissues were preserved in RNA Later (Sigma) at the time of sacrificing. Tissues were homogenized in 1 ml of Trizol (Sigma) and isolated via standard procedures. Total RNA was quantitated by NanoDrop. One μg of total RNA was converted to cDNA using a reverse transcription kit (BioRad). Total cDNA was then subjected to PCR amplification as described above.
Tissues samples were fixed in 10% neutral buffered formalin (Fisher Scientific) overnight at RT. After 24 h, formalin was then replaced with 70% ethanol and the tissues were stored at 4°C until processing. Tissues were embedded in paraffin using standard techniques. Five micrometer sections were stained with H&E by the Pathology Core Research Laboratory, University of Louisville and evaluated by a trained pathologist, Hanan Farghaly, MD.
Formalin-fixed paraffin embedded tissue sections were deparaffinized in fresh xylene and rehydrated in a graded series of ethanol. Antigen retrieval was conducted by incubating the slides in 10 mM sodium citrate (pH 6.0) at 95°C for 20 min then rinsing twice with PBS. Slides were incubated in 4 drops per section of Image-It FX Signal Enhancer (Invitrogen) for 30 min in a humidity chamber and then rinsed with PBS. Slides were blocked with 10% goat serum (Sigma) in PBS for 1 h followed by anti-PTTG diluted 1:1,500 in PBS and incubated at 4°C overnight. Slides were then washed in PBS before application of a secondary Alexa 594 labeled anti-rabbit (Invitrogen) diluted 1:500 in PBS containing 1 drop of goat serum per 5 ml and incubated for 45 min at RT in the dark, then washed three times with PBS. Images were acquired on Nikon Eclipse E400 and ACT-1.1 imaging software (Huntley, IL, USA).
Formalin-fixed paraffin embedded tissues were deparaffinized in xylene and rehydrated in a decreasing graded series of ethanol. Antigen retrieval was conducted by incubating the slides in 10 mM sodium citrate (pH 6.0) at 95°C for 20 min, then rinsed in PBS for 5 min. Slides were incubated with 0.3% hydrogen peroxide in methanol for 20 min at RT and rinsed three times in PBS for 5 min each. For proliferating cell nuclear antigen (PCNA) expression, slides were blocked using a Mouse-On-Mouse (M.O.M.) peroxidase kit (Vector Laboratories) for 1 h at RT. Blocking solution was poured off and slides were incubated in M.O.M. diluent for 5 minutes. PCNA diluted 1:2,000 (Cell Signaling) in SignalStain antibody diluent (Cell Signaling) was incubated overnight at 4°C. After washing three times in PBS for 5 min each, secondary anti-mouse biotinylated IgG from M.O.M. kit was incubated for 45 min at RT followed by 30 min incubation with streptavidin. After three washes in PBS for 5 min each, 3, 3’-diaminobenzidine (DAB, Vector Laboratories) was used to develop color. For CD31, slides were blocked using Vectastain anti-rabbit Elite ABC kit (Vector Laboratories) for 1 h at RT and then incubated with anti-CD31 (1:50, AbCam) in PBS overnight at 4°C. Vectastain anti-rabbit Elite ABC kit (Vector Laboratories) and DAB was used to develop color.
Generation of CMV-PTTG-EGFP transgenic mice
In previous attempts to generate TgPTTG under the control of promoters MISIIR and αGSU, mice did not develop visible ovarian or pituitary tumors [22, 23]. Therefore, we asked whether the level of PTTG expression was sufficient to drive tumorigenesis as the level of PTTG expression was shown to be significant for tumor growth [19, 21]. To this end we selected the non-specific strong CMV promoter to drive PTTG expression. Human PTTG cDNA was subcloned into the multiple cloning site of the N3 expression vector containing the CMV promoter and a downstream enhanced GFP (EGFP) marker gene. In order to reduce the transgene fragment size for ideal transgenic mouse production, the N3-PTTG was restricted with Ase I and Afl II restriction enzymes, resulting in the transgene fragment CMV-PTTG-EGFP (Figure 1). The transgene was sequenced to ensure authenticity of the sequence. EGFP has been shown not to impact target gene function . The transgene was microinjected into the male pronuclei of 0.5 day old Friend Virus B-Type (FVB) embryos. TgPTTG founders were identified by PCR screening of DNA extracted from the tail clip of 34 F0 mice using two different sense primers located in PTTG and one antisense primer located in EGFP (Figure 1). This resulted in the identification of 1 male (#71288) and 3 female TgPTTG founders (#71282, 71305, and 71309; Figure 2A-B). The founders were crossbred with wild type (WT) FVB mice and resultant F1 offspring were genotyped by PCR (Figure 2C-D). All founders were fertile and produced an average litter size (Table 1). However, the male and 1 female founder (#71282) failed to transmit the transgene to their offspring (F1), suggesting that the transgene did not integrate into the germ line. F1 TgPTTG males from a single line (founder #71309) were crossbred with WT females through multiple generations to create F2-F4 to generate a sufficient number of TgPTTG mice. TgPTTG males were often aggressive by 6 months of age and had to be maintained in separate cages. All mice demonstrated hyperactivity during housing.
PTTG expression in CMV-PTTG-EGFP mice
TgPTTG mice were sacrificed at 4, 6, 8, and 10 months of age along with the age-matched WT controls and tissues were harvested for RNA isolation and immunohistochemistry. Tissues selections were determined by promoter expression  and examined by reverse transcription/PCR of RNA isolated from the ovary, fallopian tube, lung, spleen, liver, and kidney (Figure 3). As expected, PTTG expression was detected in all of the tissues.
Protein expression of the transgene was determined by immunofluorescence to determine if expression was localized to any specific cell type or more broadly distributed. PTTG primary antibody raised in our laboratory  was detected with Alexa 594 secondary antibody (red). Sections were then analyzed by fluorescence microscopy using a Texas Red filter for PTTG expression and GFP filter for EGFP expression. Specificity of the PTTG antibody to human PTTG vs. murine PTTG has been addressed previously . Immunofluorescence of the fallopian tube and uterus showed intense staining in the epithelium, while in the ovary, staining was observed in stromal cells (Figure 4) in 4 months old animals. Lung, spleen, liver, and kidney showed general non-specific expression of the transgene.
Histology and immunohistochemistry of TgPTTG tissues
Formalin-fixed paraffin embedded tissues were sectioned and stained with hematoxylin and counterstained with eosin (H&E). Evaluation of the histology was performed by a licensed pathologist (HF). Tissues were selected based on CMV promoter expression  to include liver, kidney, lung, and spleen as well as additional tissues of interest including ovary, fallopian tube, and uterus. While all tissues were normal in 4 and 6 months old TgPTTG mice, pre-cancerous conditions (3 out of 15, 20%) and carcinomas (2 out of 15, 13.3%) were observed at 8 months of age. A total of 15 females were included in the TgPTTG 8 month old group and were compared with 11 WT age-matched controls. PTTG-EGFP expression was confirmed by immunofluorescence (Figure 5). Pronounced follicular cysts and corpus luteum were observed in 6 out of 15 (40%) of TgPTTG females. Pre-cancerous conditions included one female (#286) having squamous dysplasia with extensive keratinization at the transformation zone between the uterus and the cervix (Figure 6), a second female (#365) developed hyperplasia of the fallopian tube with endothelial atypia (Figure 6), while a third female (#436) developed low grade dysplasia of squamous epithelium with acute cervicitis (Figure 6). Inflammation was also observed in additional females, predominately in the cervix (2 out of 15, 13.3%) and fallopian tube causing dilation (3 out of 15, 20%). Hyperplastic and dysplastic conditions were confirmed using PCNA staining compared to age-matched controls . PCNA staining for TgPTTG #286 revealed 5% positive cells with reverse maturation of squamous epithelium of the cervix. TgPTTG #365 was 25% positive for PCNA and localized to the epithelial glands of the fallopian tube. PCNA staining for TgPTTG #436 cervix was 5-10% positive, localizing to the basal cells and showed a pattern of reverse maturation. Age-matched WT fallopian tubes and cervix were negative for PCNA demonstrating that PTTG increased proliferation. Three females (20%) developed adenomyosis of the uterus. An additional two females (13.3%) developed ovarian cancer (#434, 436; Figure 7). PCNA and CD31 staining were performed to compare proliferation and angiogenesis in TgPTTG ovarian carcinomas compared to age-matched WT animals. We decided to use a rating system for CD31 staining, where 1+ means < 25% of tissue was stained, 2+ means 25-75% of tissue was stained, and 3+ means > 75% of tissue was stained in accordance with pathology standards. TgPTTG #434 developed ovarian serous adenocarcinoma with PCNA staining showed 35% positive area and CD31 staining was 2+ (Figure 7). TgPTTG #436 developed a granulosa cell tumor and a follicular cyst with mitotic figures. In this female, PCNA staining was 5% and CD31 staining was 2+ (Figure 7). Comparatively, age-matched WT animals showed 1% PCNA staining of the ovary, which was localized to the granulosa cells of the follicle as expected, while CD31 staining was 1+ (Figure 7). A summary of PCNA and CD31 staining patterns are reported in Table 2. All other tissues were devoid of visible tumors.
Ten months old TgPTTG group included 10 females and was compared to 13 WT age-matched controls. PTTG-EGFP expression was confirmed by immunofluorescence (Figure 8). One female developed a pre-cancerous serous cyst adenoma of the ovary. Another developed serous adenocarcinoma of the ovary and fallopian tube (#381, Figure 9), while an additional female developed a tumor of ovarian follicular cells (#383, Figure 9). PCNA staining was 5-10% in both TgPTTG ovaries and 15% in age-matched WT controls which was localized to the follicles (Figure 9). CD31 staining was similar between WT ovaries and TgPTTG ovaries (1+, Figure 9). Interestingly, PTTG expression was higher in the female that developed serous adenocarcinoma vs. the female with the follicular cells tumor (Figure 8). Additionally, 1 out of 20 (5%) of TgPTTG mice developed an ectopic tumor diagnosed as a papillary serous adenocarcinoma that was 75% positive for PCNA and had significant CD31 staining (3+, Figure 9). Two other females (20%) showed atypia of epithelial cells of the fallopian tube. A summary of PCNA and CD31 staining patterns is shown in Table 3. All other tissues were devoid of visible tumors.
Transgene copy number analysis
Although unlikely, the transgene copy number could have been unstable, and therefore vary among offspring. To exclude this possibility, transgene copy number was assessed to analyze differences between TgPTTG that developed cancer and those that did not. A standard curve was generated using the N3 vector containing PTTG (Additional file 1: Figure S 1A). By calculating the size of the vector, a copy number could be assessed to the standard curve. Then, by taking 100 ng of genomic DNA isolated from the tail clip, the gene copy number was extrapolated from the standard curve as 100 ng of DNA has been reported to yield 1.67 x 104 diploid cells . We found no difference in transgene copy number between TgPTTG mice that developed cancer and those that did not develop cancer (Additional file 1: Figure S 1B).
Crossbreeding of TgPTTG with p53+/−mice and histology
P53 mutant mice were produced by a targeted neo cassette insertion into the p53 locus in the laboratory of Dr. Tyler Jacks at the Center for Cancer Research, Massachusetts Institute of Technology  and are commercially available through the Jackson Laboratory. P53+/− mice have been reported to have an 18% incidence of adenocarcinomas and a 56% incidence of sarcomas over a period of 17 months . Based on the 56 mice we observed (45 p53+/− and 11 p53−/−), four p53+/− mice (8.9%) developed sarcomas between 3 to 11 months, while nine p53−/− (81.8%) developed lymphoma and sarcomas at age 9 to 12 weeks before succumbing to their disease.
Due to the short lifespan of p53−/− mice, p53+/− mice were chosen for crossbreeding to investigate if a partner gene would increase the incidence, decrease the onset time, and/or possibly change the type of cancer in TgPTTG mice. Two male TgPTTG mice from line #71309 were crossbred with p53+/− females to maximize offspring, resulting in generation of F2 (Figure 10). Accuracy of p53 status of TgPTTG/p53−/− and TgPTTG/p53+/− was confirmed by sequencing genomic DNA. PTTG-EGFP expression was analyzed by immunofluorescence and was higher in TgPTTG/p53−/− tumors than TgPTTG/p53+/− (Figure 11). Due to tumor burden, three mice necessitated premature euthanization. Of the three, one TgPTTG/p53−/− mouse (#450) developed two teratocarcinomas at 7 weeks of age, while a second mouse developed lymphoma and two sarcomas at 11 weeks of age (#448, Figure 12). Comparatively, p53−/− mice develop lymphoma and sarcomas at 12 weeks (9 of 11). The third mouse was TgPTTG/p53+/− between TGPTTG and p53+ that developed adenocarcinoma of the fallopian tube and leiomyosarcoma with mitotic figures at 7 months of age (#272, Figure 12). PCNA and CD31 analysis was performed in these tissues. PCNA was 90% in the teratocarcinoma as well as TgPTTG/p53−/− sarcoma and 99% in the TgPTTG/p53+/− leiomyosarcoma (Figure 12). All tumors showed CD31 staining of 1+ (Figure 12).
TgPTTG/p53+/− mice aged to 8 months included 10 females. Of the TgPTTG/p53+/− females aged to 8 months, 4 out of 10 (40%) had severe dysplasia of the cervix resulting in carcinomas in situ (Figure 12) along with 1 out of 10 (10%) developing a sarcoma. PCNA staining for cervical carcinomas in situ showed 10% positive area with reverse maturation and 2+ microvessel formation. PCNA showed 99% positive area in all sarcomas, congruent with the highly aggressive nature of this tumor type.
TgPTTG/p53+/− mice aged to 10 months included 8 females. Five out of 8 (63%) females showed focal to severe cervical dysplasia resulting in carcinomas in situ, and 3 out of 8 (38%) showed dilation of the fallopian tube. Two out of 8 (25%) developed high grade leiomyosarcomas (Figure 12). All TgPTTG/p53+/− sarcomas were 99% positive for PCNA and had significant microvessel formation (CD31 staining 3+) determined by CD31 (Figure 12). Comparatively, p53+/− mice developed sarcomas between 11 to 12 months of age (2 of 28, 7%).
The timeline of tumor developments in TgPTTG, p53+/−, and TgPTTG/p53+/− is summarized in Figure 13.
PTTG has been shown in pituitary tumors to have the properties of a transforming gene activated during the early stages of neoplastic transformation, changing the cells from a normal phenotype to hyperplastic . Based on this information, a transgenic mouse expressing PTTG under the control of αGSU promoter to target the expression to the gonadotroph cells of the pituitary was created . This resulted in gonadroph hyperplasia and microadenomas with plurihormal hyperplasia, accompanied by prostatic and seminal vesicle hyperplasia, demonstrating that PTTG was a functional transforming oncogene. Since PTTG is a prominent oncogene in pituitary tumors, many investigators have identified PTTG in several other endocrine-related tumors. Its expression has been detected in endometriod carcinomas and in hyperplastic endometria . In addition to being cloned from ovarian tumors, PTTG has been identified in various ovarian tumor tissues but not in normal ovary . In addition, a mouse xenograft model of ovarian cancer showed that PTTG was crucial for tumor development . Therefore, previously our lab developed a transgenic mouse model that expresses human PTTG cDNA under the control of MISIIR. These mice presented with an increased mass of the corpus luteum as well as an increase in the serum LH and testosterone. However, despite PTTG expression in the ovary and testes, these animals developed cystic glandular hyperplasia but failed to develop visible ovarian adenocarcinomas , possible due to a weak promoter that was unable to produce the required level of PTTG protein to initiate tumorigenesis. However, we also asked if a partner gene was necessary to complete tumorigenesis as it often requires multiple gene mutations including activation or amplification of oncogenes, increased growth factors and their receptors, and/or inactivation of tumor suppressor genes, and therefore PTTG expression by itself may not be sufficient to drive tumorigenesis and may require a partner gene .
Therefore, in our current study to understand the tumorigenic potential of PTTG, we generated a transgenic mouse that constitutively overexpresses PTTG under the control of the non-specific CMV promoter to strengthen PTTG expression as the level of PTTG is critical for tumorigenesis [19, 33]. By using this approach, we were able to generate ovarian tumors in transgenic animals as early as 8 months of age (Figure 7) and continued to observe them at 10 months (Figure 9), albeit at a low incidence of ~17%. It is interesting that although the CMV promoter is a non-specific promoter, ovarian and fallopian tube tumors and papillary serous adenocarcinomas were the only observed tumor types, perhaps due to the site of integration. However, PTTG also has transactivation activity through the presence of Src-homology 3 (SH3) domains located in the proline-rich regions of the C-terminus . As such, PTTG increases the excretion of bFGF , which itself can increase ovarian cancer invasion ; therefore, PTTG itself may not directly induce tumorigenesis but acts indirectly on tissues expressing a higher level of bFGF, such as the ovary, fallopian tube, and cervix [36–38] to increase angiogenesis and stimulate expression of other activator genes, such as Ets-1 and urokinase-type plasminogen activator to promote tumor progression.
Since our incidence of tumor formation was ~17%, we cross-bred our TgPTTG mice with p53 mutant (p53+/−) mice with the assumption that p53+/− would enhance the incidence. Using this approach, TgPTTG/p53+/− animals resulted in earlier tumor development than PTTG or p53+/− alone (Figure 13) and increased the incidence of high grade leiomyosarcomas from 7% in p53+/− mice to 14% in TgPTTG/p53+/−. We also noted a significant incidence of cervical carcinomas of 63% in TgPTTG/p53+/−. Most cases of cervical cancer in women are due to human papilloma virus (HPV) infections that cause inactivation of p53 and Rb, mutations that mainly affect the squamous epithelium along the transformation zone as HPV infections require cells that are proliferating . In our TgPTTG mice, we noticed a reverse maturation of the basal squamous epithelium coupled to dysplasia. As PTTG increases cell proliferation as observed by PCNA staining, PTTG could serve to prime the basal epithelium, which could make these particular cells more susceptible to further neoplastic transformation due to alterations of additional genes, such as p53. We also noted teratocarcinomas in TgPTTG/p53−/−. While little is known about the genetic contributions to teratocarcinomas, the field theory states that normal germ cells that are placed in an environment that allows expression of the cancer phenotype have the potential to become cancerous . Constitutive overexpression of PTTG may alter the micro environment through enhanced secretion of growth factors, and thus allow normal cells to proliferate more rapidly causing transformation of normal cells to become tumorigenic leading to the formation of tumors, such as teratocarcinomas.
In our studies, we showed that PTTG is a functional oncogene that is capable of initiating transformation of normal tissue to dysplastic. Furthermore, a high expression level of PTTG was capable of inducing tumorigenesis in the ovary and other tissues leading to tumorigenesis. Coupling of TgPTTG with mutant p53 led us to conclude that the early neoplastic events (normal to dysplastic) were independent of p53 as the additional mutation did not enhance incidence of ovarian cancer; however overexpression of PTTG and loss of p53 function reduced the time of development of certain cancers, including sarcoma.
Alpha-subunit of glycoprotein hormone
Basic fibroblast growth factor
Friend Virus B-Type
Müllerian inhibitory substance type II receptor
Pituitary tumor transforming gene
- Rb+/− :
Heterozygous deletion of retinoblastoma
PTTG transgenic mice
Vascular endothelial growth factor.
Zou H, McGarry TJ, Bernal T, Kirschner MW: Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science. 1999, 285: 418-422. 10.1126/science.285.5426.418.
Vlotides G, Eigler T, Melmed S: Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev. 2007, 28: 165-186.
Hamid T, Malik MT, Kakar SS: Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells. Mol Cancer. 2005, 4: 3-10.1186/1476-4598-4-3.
Kim D, Pemberton H, Stratford AL, Buelaert K, Watkinson JC, Lopes V, Franklyn JA, McCabe CJ: Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene. 2005, 24: 4861-4866. 10.1038/sj.onc.1208659.
Kakar SS, Jennes L: Molecular cloning and characterization of the tumor transforming gene (TUTR1): a novel gene in human tumorigenesis. Cytogenet Cell Genet. 1999, 84: 211-216. 10.1159/000015261.
Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S: Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med. 1999, 5: 1317-1321. 10.1038/15275.
McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ: Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab. 2002, 87: 4238-4244. 10.1210/jc.2002-020309.
Shah PP, Fong MY, Kakar SS: PTTG induces EMT through integrin alpha(V)beta(3)-focal adhesion kinase signaling in lung cancer cells. Oncogene. 2011, 31: 3124-3135.
Shah PP, Kakar SS: Pituitary tumor transforming gene induces epithelial to mesenchymal transition by regulation of Twist, Snail, Slug, and E-cadherin. Cancer Lett. 2011, 311: 66-76. 10.1016/j.canlet.2011.06.033.
Pei L, Melmed S: Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1997, 11: 433-441. 10.1210/me.11.4.433.
Puri R, Tousson A, Chen L, Kakar SS: Molecular cloning of pituitary tumor transforming gene 1 from ovarian tumors and its expression in tumors. Cancer Lett. 2001, 163: 131-139. 10.1016/S0304-3835(00)00688-1.
McCabe CJ, Khaira JS, Boelaert K, Heaney AP, Tannahill LA, Hussain S, Mitchell R, Olliff J, Sheppard MC, Franklyn JA, Gittoes NJ: Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol (Oxf). 2003, 58: 141-150. 10.1046/j.1365-2265.2003.01598.x.
Heaney AP, Melmed S: Pituitary tumour transforming gene: a novel factor in pituitary tumour formation. Baillieres Best Pract Res Clin Endocrinol Metab. 1999, 13: 367-380. 10.1053/beem.1999.0028.
Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S: Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet. 2000, 355: 716-719. 10.1016/S0140-6736(99)10238-1.
Boelaert K, Tannahill LA, Bulmer JN, Kachilele S, Chan SY, Kim D, Gittoes NJ, Franklyn JA, Kilby MD, McCabe CJ: A potential role for PTTG/securin in the developing human fetal brain. FASEB J. 2003, 17: 1631-1639. 10.1096/fj.02-0948com.
Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M: PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast. 2004, 13: 80-81. 10.1016/j.breast.2003.09.008.
Genkai N, Homma J, Sano M, Tanaka R, Yamanaka R: Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. Oncol Rep. 2006, 15: 1569-1574.
Panguluri SK, Yeakel C, Kakar SS: PTTG: an important target gene for ovarian cancer therapy. J Ovarian Res. 2008, 1: 6-10.1186/1757-2215-1-6.
El-Naggar SM, Malik MT, Kakar SS: Small interfering RNA against PTTG: a novel therapy for ovarian cancer. Int J Oncol. 2007, 31: 137-143.
Chesnokova V, Kovacs K, Castro AV, Zonis S, Melmed S: Pituitary hypoplasia in Pttg−/− mice is protective for Rb+/− pituitary tumorigenesis. Mol Endocrinol. 2005, 19: 2371-2379. 10.1210/me.2005-0137.
Cho-Rok J, Yoo J, Jang YJ, Kim S, Chu IS, Yeom YI, Choi JY, Im DS: Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology. 2006, 43: 1042-1052. 10.1002/hep.21137.
El-Naggar SM, Malik MT, Martin A, Moore JP, Proctor M, Hamid T, Kakar SS: Development of cystic glandular hyperplasia of the endometrium in Mullerian inhibitory substance type II receptor-pituitary tumor transforming gene transgenic mice. J Endocrinol. 2007, 194: 179-191. 10.1677/JOE-06-0036.
Abbud RA, Takumi I, Barker EM, Ren SG, Chen DY, Wawrowsky K, Melmed S: Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol Endocrinol. 2005, 19: 1383-1391. 10.1210/me.2004-0403.
Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD, Melmed S: Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1999, 13: 156-166. 10.1210/me.13.1.156.
Donangelo I, Gutman S, Horvath E, Kovacs K, Wawrowsky K, Mount M, Melmed S: Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology. 2006, 147: 4781-4791. 10.1210/en.2006-0544.
Aiba-Masago S, Baba S, Li RY, Shinmura Y, Kosugi I, Arai Y, Nishimura M, Tsutsui Y: Murine cytomegalovirus immediate-early promoter directs astrocyte-specific expression in transgenic mice. Am J Pathol. 1999, 154: 735-743. 10.1016/S0002-9440(10)65320-5.
Kakar SS, Chen L, Puri R, Flynn SE, Jennes L: Characterization of a polyclonal antibody to human pituitary tumor transforming gene 1 (PTTG1) protein. J Histochem Cytochem. 2001, 49: 1537-1546. 10.1177/002215540104901207.
Coltrera MD, Zarbo RJ, Sakr WA, Gown AM: Markers for dysplasia of the upper aerodigestive tract. Suprabasal expression of PCNA, p53, and CK19 in alcohol-fixed, embedded tissue. Am J Pathol. 1992, 141: 817-825.
Joshi M, Keith Pittman H, Haisch C, Verbanac K: Real-time PCR to determine transgene copy number and to quantitate the biolocalization of adoptively transferred cells from EGFP-transgenic mice. Biotechniques. 2008, 45: 247-258. 10.2144/000112913.
Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA: Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994, 4: 1-7. 10.1016/S0960-9822(00)00002-6.
Wang YK, Cui N, Li J, Luo B: Expression of pituitary tumor-transforming gene in endometrial carcinoma. Zhonghua Fu Chan Ke Za Zhi. 2004, 39: 538-542.
Kakar SS, Malik MT: Suppression of lung cancer with siRNA targeting PTTG. Int J Oncol. 2006, 29: 387-395.
Wang Z, Melmed S: Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. J Biol Chem. 2000, 275: 7459-7461. 10.1074/jbc.275.11.7459.
Li T, Jiang S: Effect of bFGF on invasion of ovarian cancer cells through the regulation of Ets-1 and urokinase-type plasminogen activator. Pharm Biol. 2010, 48: 161-165. 10.3109/13880200903062630.
Ergin K, Gursoy E, Basimoglu Koca Y, Basaloglu H, Seyrek K: Immunohistochemical detection of insulin-like growth factor-I, transforming growth factor-beta2, basic fibroblast growth factor and epidermal growth factor-receptor expression in developing rat ovary. Cytokine. 2008, 43: 209-214. 10.1016/j.cyto.2008.05.013.
Gabler C, Lauer B, Einspanier A, Schams D, Einspanier R: Detection of mRNA and immunoreactive proteins for acidic and basic fibroblast growth factor and expression of the fibroblast growth factor receptors in the bovine oviduct. J Reprod Fertil. 1997, 109: 213-221. 10.1530/jrf.0.1090213.
Luo CF, Hong HL, Lu YL, Wang H, Liu MQ: Expressions of bFGF and PTEN in cervical carcinoma and their clinical significance. Zhonghua Zhong Liu Za Zhi. 2010, 32: 533-538.
Jayshree RS, Sreenivas A, Tessy M, Krishna S: Cell intrinsic & extrinsic factors in cervical carcinogenesis. Indian J Med Res. 2009, 130: 286-295.
Sell S: On the stem cell origin of cancer. Am J Pathol. 2010, 176: 2584-2494. 10.2353/ajpath.2010.091064.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/532/prepub
The authors would like to thank Dr. Jason Chesney for his critical input and Dr. John Eaton for critical editing of the manuscript. Authors are also thankful to Penny White and Renu Kakar for their technical assistance. This work was supported by a grant from the National Institutes of Health, National Cancer Institute, CA124630 (SSK).
The authors declare no competing interests.
MYF designed and performed experiments, analyzed and interpreted the data, and drafted the manuscript. HF analyzed and interpreted the data. SSK conceptualized and designed experiments, analyzed and interpreted the data, and helped in drafting the manuscript. All authors read and approved the final manuscript.
Electronic supplementary material
Additional file 1: Figure S1. Transgene copy number analysis of TgPTTG mice that developed cancer and TgPTTG mice that did not. (A) Standard curve generated from N3 cloning vector containing PTTG in the multiple cloning site. (B) Real-time PCR analysis of transgene copy number extrapolated from standard curve plotted as average ± SD. TgPTTG mice were selected from 8 months – 10 months. N = 3 for no cancer, N = 6 for cancer. (TIFF 4 MB)
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Fong, M.Y., Farghaly, H. & Kakar, S.S. Tumorigenic potential of pituitary tumor transforming gene (PTTG) in vivoinvestigated using a transgenic mouse model, and effects of cross breeding with p53 (+/−) transgenic mice. BMC Cancer 12, 532 (2012). https://doi.org/10.1186/1471-2407-12-532
- Transgenic mice